GLAUKOS CORP (GKOS) Stock Fundamental Analysis

NYSE:GKOS • US3773221029

109.47 USD
+2.73 (+2.56%)
At close: Feb 13, 2026
109.47 USD
0 (0%)
After Hours: 2/13/2026, 8:13:31 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, GKOS scores 4 out of 10 in our fundamental rating. GKOS was compared to 185 industry peers in the Health Care Equipment & Supplies industry. GKOS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GKOS shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • GKOS had negative earnings in the past year.
  • GKOS had a negative operating cash flow in the past year.
  • GKOS had negative earnings in each of the past 5 years.
  • In the past 5 years GKOS reported 4 times negative operating cash flow.
GKOS Yearly Net Income VS EBIT VS OCF VS FCFGKOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • GKOS has a Return On Assets of -8.77%. This is in the better half of the industry: GKOS outperforms 63.44% of its industry peers.
  • Looking at the Return On Equity, with a value of -11.39%, GKOS is in the better half of the industry, outperforming 67.20% of the companies in the same industry.
Industry RankSector Rank
ROA -8.77%
ROE -11.39%
ROIC N/A
ROA(3y)-13.08%
ROA(5y)-11.18%
ROE(3y)-22.32%
ROE(5y)-18.69%
ROIC(3y)N/A
ROIC(5y)N/A
GKOS Yearly ROA, ROE, ROICGKOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20

1.3 Margins

  • GKOS's Gross Margin of 76.87% is amongst the best of the industry. GKOS outperforms 88.71% of its industry peers.
  • In the last couple of years the Gross Margin of GKOS has declined.
  • GKOS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.81%
GM growth 5Y-2.05%
GKOS Yearly Profit, Operating, Gross MarginsGKOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • GKOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, GKOS has more shares outstanding
  • The number of shares outstanding for GKOS has been increased compared to 5 years ago.
  • The debt/assets ratio for GKOS has been reduced compared to a year ago.
GKOS Yearly Shares OutstandingGKOS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
GKOS Yearly Total Debt VS Total AssetsGKOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • GKOS has an Altman-Z score of 15.91. This indicates that GKOS is financially healthy and has little risk of bankruptcy at the moment.
  • GKOS's Altman-Z score of 15.91 is amongst the best of the industry. GKOS outperforms 94.62% of its industry peers.
  • GKOS has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.09, GKOS is doing good in the industry, outperforming 65.59% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 15.91
ROIC/WACCN/A
WACC9.58%
GKOS Yearly LT Debt VS Equity VS FCFGKOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • GKOS has a Current Ratio of 5.20. This indicates that GKOS is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 5.20, GKOS is doing good in the industry, outperforming 79.57% of the companies in the same industry.
  • A Quick Ratio of 4.47 indicates that GKOS has no problem at all paying its short term obligations.
  • GKOS has a better Quick ratio (4.47) than 79.03% of its industry peers.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 4.47
GKOS Yearly Current Assets VS Current LiabilitesGKOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • GKOS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.11%, which is quite impressive.
  • GKOS shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.38%.
  • The Revenue has been growing by 10.10% on average over the past years. This is quite good.
EPS 1Y (TTM)52.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)30.38%
Revenue growth 3Y9.26%
Revenue growth 5Y10.1%
Sales Q2Q%38.14%

3.2 Future

  • The Earnings Per Share is expected to grow by 27.44% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, GKOS will show a very strong growth in Revenue. The Revenue will grow by 27.86% on average per year.
EPS Next Y56.19%
EPS Next 2Y34.81%
EPS Next 3Y32.2%
EPS Next 5Y27.44%
Revenue Next Year32.07%
Revenue Next 2Y27.26%
Revenue Next 3Y27.42%
Revenue Next 5Y27.86%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GKOS Yearly Revenue VS EstimatesGKOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
GKOS Yearly EPS VS EstimatesGKOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GKOS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GKOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GKOS Price Earnings VS Forward Price EarningsGKOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GKOS Per share dataGKOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as GKOS's earnings are expected to grow with 32.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.81%
EPS Next 3Y32.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • GKOS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GLAUKOS CORP

NYSE:GKOS (2/13/2026, 8:13:31 PM)

After market: 109.47 0 (0%)

109.47

+2.73 (+2.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-29
Earnings (Next)02-17
Inst Owners100.65%
Inst Owner Change-91.78%
Ins Owners3.3%
Ins Owner Change1.48%
Market Cap6.29B
Revenue(TTM)469.82M
Net Income(TTM)-87.61M
Analysts83.64
Price Target135.37 (23.66%)
Short Float %4.01%
Short Ratio2.74
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.11%
Min EPS beat(2)11.08%
Max EPS beat(2)39.14%
EPS beat(4)3
Avg EPS beat(4)21.48%
Min EPS beat(4)-2.27%
Max EPS beat(4)39.14%
EPS beat(8)5
Avg EPS beat(8)12.2%
EPS beat(12)8
Avg EPS beat(12)9.6%
EPS beat(16)11
Avg EPS beat(16)5.59%
Revenue beat(2)2
Avg Revenue beat(2)6.09%
Min Revenue beat(2)5.35%
Max Revenue beat(2)6.84%
Revenue beat(4)4
Avg Revenue beat(4)4.22%
Min Revenue beat(4)2.01%
Max Revenue beat(4)6.84%
Revenue beat(8)8
Avg Revenue beat(8)4.2%
Revenue beat(12)12
Avg Revenue beat(12)4.2%
Revenue beat(16)16
Avg Revenue beat(16)4.61%
PT rev (1m)7.27%
PT rev (3m)12.4%
EPS NQ rev (1m)6.93%
EPS NQ rev (3m)-2.87%
EPS NY rev (1m)2%
EPS NY rev (3m)0.7%
Revenue NQ rev (1m)5.35%
Revenue NQ rev (3m)5.01%
Revenue NY rev (1m)1.31%
Revenue NY rev (3m)1.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.38
P/FCF N/A
P/OCF N/A
P/B 8.17
P/tB 14.33
EV/EBITDA N/A
EPS(TTM)-1.02
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.77
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS8.18
BVpS13.4
TBVpS7.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.77%
ROE -11.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.87%
FCFM N/A
ROA(3y)-13.08%
ROA(5y)-11.18%
ROE(3y)-22.32%
ROE(5y)-18.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.81%
GM growth 5Y-2.05%
F-Score5
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.31%
Cap/Sales 4.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.2
Quick Ratio 4.47
Altman-Z 15.91
F-Score5
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)54.99%
Cap/Depr(5y)69.95%
Cap/Sales(3y)6.26%
Cap/Sales(5y)7.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y56.19%
EPS Next 2Y34.81%
EPS Next 3Y32.2%
EPS Next 5Y27.44%
Revenue 1Y (TTM)30.38%
Revenue growth 3Y9.26%
Revenue growth 5Y10.1%
Sales Q2Q%38.14%
Revenue Next Year32.07%
Revenue Next 2Y27.26%
Revenue Next 3Y27.42%
Revenue Next 5Y27.86%
EBIT growth 1Y23.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.24%
EBIT Next 3Y40.06%
EBIT Next 5Y39.25%
FCF growth 1Y41.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.76%
OCF growth 3YN/A
OCF growth 5YN/A

GLAUKOS CORP / GKOS FAQ

Can you provide the ChartMill fundamental rating for GLAUKOS CORP?

ChartMill assigns a fundamental rating of 4 / 10 to GKOS.


What is the valuation status for GKOS stock?

ChartMill assigns a valuation rating of 1 / 10 to GLAUKOS CORP (GKOS). This can be considered as Overvalued.


How profitable is GLAUKOS CORP (GKOS) stock?

GLAUKOS CORP (GKOS) has a profitability rating of 2 / 10.